How sponsors can meet the FDA’s d iversity action plan requirements

This whitepaper is brought to you by Quest Diagnostics.

How sponsors can meet the FDA’s diversity action plan requirements

The U.S. is imposing requirements to ensure clinical trial populations match each drug’s intended use. For pharma companies to comply with diversity action plan requirements, they must have access to data to define the population affected by the targeted disease. By knowing the details, sponsors can design diversity action plans and recruit and enroll the appropriate audience for their clinical trials.
Faced with the new requirements, forward-thinking sponsors are retooling their enrollment strategies to understand the age, gender, location, race and ethnicity of potential trial participants and ensure their clinical trial populations represent the intended use. This whitepaper explains: